Your question is a pertinent one; if you read posts prior to the most recent one you will note that mention is made of the continuing uncertainty of the full roll-out of the new remuneration model and lack of company guidance. Notwithstanding the new remuneration model's significant detrimental impact on earnings, if you also read the ASX release closely you will note the company was expecting an increase in earnings prior to the intravitreal injections hit i.e. ebitda earnings were expected to exceed the $27m achieved in 2012 (full yr effect the 3 recently recruited doctors, continued underlying revenue growth of existing business etc). The company is likely to release its 2013 forecast at the agm, being 26 November, which will provide clarity.
VEI Price at posting:
37.3¢ Sentiment: None Disclosure: Not Held
